VS-505

Shanghai Alebund Pharmaceuticals Limited · Phase 2 active Small molecule

At a glance

Generic name	VS-505
Sponsor	Shanghai Alebund Pharmaceuticals Limited
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients (PHASE2)
A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VS-505 CI brief — competitive landscape report
VS-505 updates RSS · CI watch RSS
Shanghai Alebund Pharmaceuticals Limited portfolio CI